Overview

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer. Researchers also want to find out if the combination of nivolumab, ipilimumab and nintedanib is safe and tolerable.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Treatments:

Ipilimumab
Nintedanib
Nivolumab